Background The clinical impact of different prophylactic anticoagulation regimens among
hospitalized patients with coronavirus disease 2019 (COVID-19) remains unclear. We …

The COVID-19 pandemic has led to numerous negative implications for all aspects of
society. Although COVID-19 is a predominant lung disease, in 10–30% of cases, it is …

Purpose To describe bleeding and thrombotic events and their risk factors in patients
receiving extracorporeal membrane oxygenation (ECMO) for severe coronavirus disease …

Thromboprophylaxis with low molecular weight heparin in hospitalized patients with COVID-
19 is mandatory, unless contraindicated. Given the links between inflammation and …

Background Anticoagulation in hospitalized COVID-19 patients has been associated with
survival benefit; however, the optimal anticoagulant strategy has not yet been defined. The …

BACKGROUND Evidence regarding the safety and efficacy of anticoagulant
thromboprophylaxis among pediatric patients hospitalized for coronavirus disease 2019 …

Background: The treatment of COVID-19 patients with heparin is not always effective in
preventing thrombotic complications, but can also be associated with bleeding …

COVID‐19 (severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2]) is associated
with coagulopathy through numerous mechanisms. The reported incidence of venous …

Background The aim of this study was to detail the incidence of venous thromboembolism
(VTE) in patients hospitalised with COVID-19 in England. Methods This was an exploratory …

Background The coronavirus disease 2019 (COVID-19) causes extensive coagulopathy and
a potential benefit of anticoagulation therapy has been documented for prevention of …